{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_5cdece175ef85b6602c4950c4b2deed12ad15b6ac189565789a9ba098a14243a","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_5cdece175ef85b6602c4950c4b2deed12ad15b6ac189565789a9ba098a14243a","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"3d88ef4c58cf60ebcde18298ee6dfcf55ecaf1cb3acd9b685a556835b6f191d5","published":"Tue, 26 May 2026 00:00:00 -0400","receipt_hash":"3d88ef4c58cf60ebcde18298ee6dfcf55ecaf1cb3acd9b685a556835b6f191d5","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"3d88ef4c58cf60ebcde18298ee6dfcf55ecaf1cb3acd9b685a556835b6f191d5","observed_at":"2026-05-26T04:43:39.018238Z","parent_run_hash":"dca8dedd754ad6a1772113d6b97ee4f4ab9a0afbdeb44aaace5ff2d2446b164b","published":"Tue, 26 May 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2605.24045v1 Announce Type: cross \nAbstract: Protein-ligand modeling underpins computational drug discovery and molecular design. Existing protein-ligand benchmarks typically evaluate whether a protein and ligand interact and how strongly they bind, through tasks such as binary binding prediction and affinity regression. However, these evaluations provide limited evidence of whether models can localize binding sites or identify the non-covalent interactions underlying molecular recognition. To address this gap, we introduce InteractBind, a large-scale protein-ligand dataset comprising approximately 100k protein-ligand pairs, together with a benchmark for fine-grained evaluation. The core fine-grained task is that of binding-site localization, which uses protein-residue and ligand-atom interaction maps spanning six major types of non-covalent interactions to assess whether model-derived interaction maps localize binding sites. InteractBind further includes binding affinity and pro","title":"A Large-Scale Dataset and Benchmark: Do Protein-Ligand Models Learn Binding Sites or Just Binding Likelihood?","url":"https://arxiv.org/abs/2605.24045","vendor":"arxiv_cs_ai"},"summary":"arXiv:2605.24045v1 Announce Type: cross \nAbstract: Protein-ligand modeling underpins computational drug discovery and molecular design. Existing protein-ligand benchmarks typically evaluate whether a protein and ligand interact and how strongly they bind, through tasks such as binary binding prediction and affinity regression. However, these evaluations provide limited evidence of whether models can localize binding sites or identify the non-covalent interactions underlying molecular recognition. To address this gap, we introduce InteractBind, a large-scale protein-ligand dataset comprising approximately 100k protein-ligand pairs, together with a benchmark for fine-grained evaluation. The core fine-grained task is that of binding-site localization, which uses protein-residue and ligand-atom interaction maps spanning six major types of non-covalent interactions to assess whether model-derived interaction maps localize binding sites. InteractBind further includes binding affinity and pro","title":"A Large-Scale Dataset and Benchmark: Do Protein-Ligand Models Learn Binding Sites or Just Binding Likelihood?","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-05-26T04:43:39Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2605.24045"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:76d9a0361366049cebd11a675481b56a2e7a9e97f417095144fb52eda99b60b014bcd3d3c30cad008d99e741ecfcb57b579ac301e49482161a9b39289fe2520c","signer":"crovia.substrate","subject":{"observed_at":"2026-05-26T04:43:39Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2605.24045"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"bd3fd90398a791c5af42006afdcc160c21633b16b0c888ac73166c5cec0abfd1","leaf_index":151495,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"96113b721508e65995221c9284a0ef22a7c3c146d82207c5c4064994ab4513eb","side":"left"},{"sibling":"c2584d2f91f042f87f4e6d2cb97be7501d46edbf35bbd99b7321b7b550af80b6","side":"left"},{"sibling":"6181631b0c8d6158d6b305a81793c526b2025e44bb35cf6c737860564447ed8f","side":"left"},{"sibling":"57ce25939ec2d7f39f599dde87a6062566bddaefde63330b0afe6b0d73ba6eb5","side":"right"},{"sibling":"f71c7b990f96bc9bb3718607ce71fe03d944b4539d76ad6880b5e3efaa17d400","side":"right"},{"sibling":"5666db2d3a86501eafdaaf254ad5327a7576db6e8ce351966b2b7940db4bf985","side":"right"},{"sibling":"aca2ea5485625e14e9749df76cdae0268d37544ceeea42aec677e7b6cb11725a","side":"left"},{"sibling":"12607c0dd56c2db51bf46dd95ab0fe795f3f832d068cd7268fed3aeeb8a7cc29","side":"left"},{"sibling":"a808644c9a09dd75253c6c0ba9275dc94a6b6451ad5184ebdafda4a2722b36a5","side":"left"},{"sibling":"fdd22ebd87e5ba37d1153e47753a63818abb25df8fe45dbf735ba5c512c3355b","side":"left"},{"sibling":"cf593c482d17d202b94914915d0c65fb8713053548db64771d0ec5dbb404a07f","side":"left"},{"sibling":"134949308b15cffd6792ee2cf678119af34d69a64764d7c89cd47573c94e1cda","side":"left"},{"sibling":"e20a7391fed5b5f3b675af68344a3f5b050d6701e127b7db010af3941e59dfdb","side":"right"},{"sibling":"e5893793e3591ed7f5e58ca94ffcfba46bb30f69fb1c25d5ba8ef49eb99f9126","side":"right"},{"sibling":"35ca36cee447f0ef7064a25d55f59357c66901e31427729c4c1d8b14aa8adb6c","side":"left"},{"sibling":"e3eecaf996dbe7229a7bb1d234c97aea97a252c5f7c89f8547b6d091db0f0e40","side":"right"},{"sibling":"55bcbd4da3e20d93931f7e58673f10232e81a5b1514d7396cb4b71e8f95788d0","side":"right"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":152106,"merkle_root":"ac5182c6f3dd09931f2a689df5f4be36df7b55e55bcf106e195671f5ed55fd8f","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260526T053701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-05-26T05:37:34Z","sig_algorithm":"ed25519","signature":"a401243fbd2c077d29a623c6ef616c78fbd5c8ce1930afa7af7165b2386e5a8cf15d5094983a1c962e71b27b911a3f3ce09c8cfab9393be2ce5ce8ee6513da06","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_5cdece175ef85b6602c4950c4b2deed12ad15b6ac189565789a9ba098a14243a"}}